The results of network pharmacology research supported that the potential mechanism of GFPs in the treatment of EMs might be inflammatory pathways, such as, TNF signaling pathway (p<0.01) and NF-kappa B signaling pathway (p<0.01). The gene discussed is TNF; the disease is eosinophilia-myalgia syndrome.